off brand semaglutide Wegovy sales took a hit this year. Novo's CEO blames off-brand competition Should You Buy Off-Brand Semaglutide

The mechanisms of H 2 S release from these drugs merit study

The wide-ranging mandate is unlikely to have an immediate impact on the high cost of health care in the US

The drug has mild side effects, such as hypertrichosis, or excessive hair growth, and hyperglycemia

Here are the most common reasons people and their doctors decide the change makes sense: Have hit a weight loss plateau after several months on Tirzepatide Want a treatment that targets three hormone receptors rather than two Need stronger blood sugar management alongside weight control Are looking for a medication that may also boost energy expenditure Your current health status, treatment history, and personal goals all factor into whether switching from Tirzepatide to Retatrutide is the right move

In October 2024, Novo Nordisk formally asked the FDA to ban the production of compounded semaglutide and requested that the agency move the drug to its Demonstrable Difficulties for Compounding (DDC) list

Pharmaceuticals 16 , 664 (2023)